NCT06044467View on ClinicalTrials.gov

The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 11, 2018

Primary Completion Date

April 27, 2020

Study Completion Date

April 27, 2020

Conditions

Nonalcoholic Fatty Liver Disease

Interventions

DRUG

Anti-human CCL24 monoclonal antibody (CM-101) - Part One

DRUG

Anti-human CCL24 monoclonal antibody (CM-101) - Part Two

DRUG

Placebo - Study Part One

Placebo Comparator

DRUG

Placebo - Study Part Two

Placebo Comparator

Trial Locations (1)

91120

Hadassah University Hospital - Ein Kerem, Jerusalem

All Listed Sponsors

lead

ChemomAb Ltd.

INDUSTRY

NCT06044467 - The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects | Biotech Hunter | Biotech Hunter